tirzepatide semaglutide user reviews comparison vs. for Weight Loss: Results, Side Effects & How to Choose A new systematic review compared

Say goodbye to dullness, toxins, and chronic fatiguediscover the transformative benefits of optimized antioxidant levels tailored just for you

At the index date in GLP-1 RA vs SGLT-2 inhibitor cohort, GLP-1 RA users were generally younger (median age 55 years [25-75 percentile: 45-65] vs 66 years [25-75 percentile: 57-74] more often female (59% vs 36%) and had a higher level of education compared with SGLT-2 inhibitor users (21% vs 15% were within ISCED level 6-8)

2025 Feb 21;14(1):36

But right now, state employees and people on MassHealth are petrified. All carriers with the Massachusetts Health Connector decided to stop covering GLP-drugs for 2026 strictly for weight loss, and additional GLP-1 cost pressure could come from MassHealth